(31 days)
Not Found
No
The device description details a traditional immunoassay based on antibody reactions and visual interpretation of colored lines, with no mention of computational analysis, algorithms, or learning processes.
No.
The device is a diagnostic test for pregnancy, not a therapeutic device designed to treat a condition.
Yes
The device detects human Chorionic Gonadotropin (hCG) in urine to aid in the determination of pregnancy, which is a diagnostic purpose.
No
The device description clearly outlines a physical test strip that utilizes chemical reactions and visual interpretation of colored lines to detect hCG. There is no mention of any software component.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states "for the qualitative detection of human Chorionic Gonadotropin (hCG) in urine to aid in the determination of pregnancy." This involves testing a sample (urine) taken from the human body to provide information about a physiological state (pregnancy).
- Device Description: The description details how the test works by analyzing a urine sample using antibodies to detect hCG. This is a classic example of an in vitro diagnostic method.
- Sample Type: The device uses urine, which is a biological sample taken from the body.
- Purpose: The purpose is to "aid in the determination of pregnancy," which is a diagnostic purpose.
The fact that it is for "over-the-counter consumer use" and doesn't involve image processing, AI, or specific anatomical sites doesn't change its classification as an IVD. IVDs encompass a wide range of tests, from complex laboratory analyzers to simple home-use tests like pregnancy tests.
N/A
Intended Use / Indications for Use
The ACON SPECTRUM hCG Midstream Pregnancy Test is for the qualitative detection of human Chorionic Gonadotropin (hCG) in urine to aid in the determination of pregnancy. It is for over-the-counter consumer use.
Product codes (comma separated list FDA assigned to the subject device)
LCX
Device Description
The test utilizes a combination of mouse monoclonal antibody conjugated with a proprietary dye-binding system and goat polyclonal antibody to qualitatively detect elevated levels of hCG in urine samples. Test may be done by applying sample and observing visually for the formation of colored lines. After sample application, specimen migrates via capillary action along the components of the test. During migration, hCG molecule in the sample reacts with the monoclonal hCG antibodies-dye conjugate, and also reacts with the polyclonal hCG antibody striped down at the test region of the membrane to form an antibody-antigen-antibody-dye complex as a colored test line. Therefore, a colored line forms in the test (T) region indicates a positive result; while absence of this colored line indicates a negative result.
To serve as a procedural control, if the test has been performed properly, a GREEN colored zone in the control (C) region will always be cleared to expose a RED line, indicating adequate sample volume and proper wicking, regardless of the presence of hCG. The presence of the green dye or absence of the red control line in the C region indicates that the test result is "invalid".
The ACON SPECTRUM hCG Midstream Pregnancy Test qualitatively detects hCG in urine sample with a designated cutoff hCG concentration of 25 mIU/mL. The cutoff concentration of this test has been standardized to the World Health Organization Fourth International Standard for Chorionic Gonadotropin (NIBSC Code: 75/589). The addition of LH (300 mIUmL), FSH (1,000 mIU/mL), and TSH (1,000 µIU/mL) to negative (0 mIUmL hCG) and positive (25 mIU/mL hCG) urine samples showed no interference in correctly reading the expected test results.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
over-the-counter consumer use
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
A consumer field study conducted in the U.S. by consumers with varying social-economic backgrounds demonstrated performance equivalency between the current ACON Midstream Pregnancy Test and the new ACON SPECTRUM hCG Midstream Pregnancy Test. A retrospective focus group study on reproducibility and precision also demonstrated high degree of correlation between the current ACON Midstream Pregnancy Test and the new ACON SPECTRUM hCG Midstream Pregnancy Test. The vast majority of the participants also found the new ACON SPECTRUM hCG Midstream Pregnancy Test very easy to use, and that they have had no trouble understanding the labeling, reading the instructions, or interpreting the results.
Additional laboratory study results on performance including specificity, interference substances, urinary pH, urinary specific gravity, dose hook effect, sample and dip time flexibility, and urination studies are also included in this submission. These results indicate that the ACQN SPECTRUM hCG Midstream Pregnancy Test is robust and will give accurate results under many adverse conditions.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.1155 Human chorionic gonadotropin (HCG) test system.
(a)
Human chorionic gonadotropin (HCG) test system intended for the early detection of pregnancy —(1)Identification. A human chorionic gonadotropin (HCG) test system is a device intended for the early detection of pregnancy is intended to measure HCG, a placental hormone, in plasma or urine.(2)
Classification. Class II.(b)
Human chorionic gonadotropin (HCG) test system intended for any uses other than early detection of pregnancy —(1)Identification. A human chorionic goadotropin (HCG) test system is a device intended for any uses other than early detection of pregnancy (such as an aid in the diagnosis, prognosis, and management of treatment of persons with certain tumors or carcinomas) is intended to measure HCG, a placental hormone, in plasma or urine.(2)
Classification. Class III.(3)
Date PMA or notice of completion of a PDP is required. As of the enactment date of the amendments, May 28, 1976, an approval under section 515 of the act is required before the device described in paragraph (b)(1) may be commercially distributed. See § 862.3.
0
510(k) Summary XV.
Device Names:
ACON SPECTRUM hCG Midstream Pregnancy Test
Common Name:
Pregnancy Test Kit, Over-the-Counter
Medical Specialty:
Clinical Chemistry
Intended Use:
The ACON SPECTRUM hCG Midstream Pregnancy Test is for the qualitative detection of human Chorionic Gonadotropin (hCG) in urine to aid in the determination of pregnancy. It is for over-the-counter consumer use.
Device Description:
The test utilizes a combination of mouse monoclonal antibody conjugated with a proprietary dye-binding system and goat polyclonal antibody to qualitatively detect elevated levels of hCG in urine samples. Test may be done by applying sample and observing visually for the formation of colored lines. After sample application, specimen migrates via capillary action along the components of the test. During migration, hCG molecule in the sample reacts with the monoclonal hCG antibodies-dye conjugate, and also reacts with the polyclonal hCG antibody striped down at the test region of the membrane to form an antibody-antigen-antibody-dye complex as a colored test line. Therefore, a colored line forms in the test (T) region indicates a positive result; while absence of this colored line indicates a negative result.
To serve as a procedural control, if the test has been performed properly, a GREEN colored zone in the control (C) region will always be cleared to expose a RED line, indicating adequate sample volume and proper wicking, regardless of the presence of hCG. The presence of the green dye or absence of the red control line in the C region indicates that the test result is "invalid".
The ACON SPECTRUM hCG Midstream Pregnancy Test qualitatively detects hCG in urine sample with a designated cutoff hCG concentration of 25 mIU/mL. The cutoff
1
concentration of this test has been standardized to the World Health Organization Fourth International Standard for Chorionic Gonadotropin (NIBSC Code: 75/589). The addition of LH (300 mIUmL), FSH (1,000 mIU/mL), and TSH (1,000 µIU/mL) to negative (0 mIUmL hCG) and positive (25 mIU/mL hCG) urine samples showed no interference in correctly reading the expected test results.
Clinical Studies:
A consumer field study conducted in the U.S. by consumers with varying socialeconomic backgrounds demonstrated performance equivalency between the current ACON Midstream Pregnancy Test and the new ACON SPECTRUM hCG Midstream Pregnancy Test. A retrospective focus group study on reproducibility and precision also demonstrated high degree of correlation between the current ACON Midstream Pregnancy Test and the new ACON SPECTRUM hCG Midstream Pregnancy Test. The vast majority of the participants also found the new ACON SPECTRUM hCG Midstream Pregnancy Test very easy to use, and that they have had no trouble understanding the labeling, reading the instructions, or interpreting the results.
Additional Laboratory Studies:
Additional laboratory study results on performance including specificity, interference substances, urinary pH, urinary specific gravity, dose hook effect, sample and dip time flexibility, and urination studies are also included in this submission. These results indicate that the ACQN SPECTRUM hCG Midstream Pregnancy Test is robust and will give accurate results under many adverse conditions.
Substantial Equivalency on Performance:
The overall performance data indicate that the new ACON SPECTRUM hCG Midstream Pregnancy Test is safe, effective and substantially equivalent to the current ACON Midstream Pregnancy Test (K983090) legally sold on the U. S. market.
Contact Information:
Edward Tung, Ph.D. Regulatory Affairs ACON Laboratories, Inc. San Diego, CA 92121
Tel. 858-535-2030 Ext. 1072; Fax 858-535-2038 Email: etung@aconlabs.com
2
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/2/Picture/1 description: The image contains the text "Public Health Service". The text is in a simple, sans-serif font and is horizontally aligned. The words are stacked on a single line and are easily readable.
Image /page/2/Picture/2 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three stripes forming its body and wing. The eagle is positioned within a circular border. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" is arranged around the upper portion of the circle.
SEP - 9 2004
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Edward Tung, Ph.D. Regulatory Affairs ACON Laboratories, Inc. 4108 Sorrento Valley Blvd. San Diego, CA 92121
Re: K042151
Trade/Device Name: ACON SPECTRUM hCG Midstream Pregnancy Test Regulation Number: 21 CFR 862.1155 Regulation Name: Human Chorionic gonadotropin (HCG) test system Regulatory Class: Class II Product Code: LCX Dated: August 5, 2004 Received: August 9, 2004
Dear Dr. Tung:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
3
Page 2
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours,
Jean M. Cooper US, Div.
Jean M. Cooper, MS, D.V.M. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
4
Indications for Use
| 510(k) Number: | K042151 |
|---|---|
| Device Name: | ACON SPECTRUM hCG Midstream Pregnancy Test |
"Indications for Use": The ACON SPECTRUM hCG Midstream Pregnancy Test is
intended for the qualitative identification of the elevated level of
human Chorionic Gonadotropin (hCG) in urine to aid in the
determination of pregnancy. It is for over-the-counter consumer
use.
Prescription Use (Part 21 CFR 801 Subpart D) AND/OR
x Over-The-Counter Use _________________________________________________________________________________________________________________________________________________________ (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)
Carol C. Benson
Division Sign-Off
Office of In Vitro Diagnostic Device Evaluation and Safety
510(k) _
Page 1 of ____________________________________________________________________________________________________________________________________________________________________